Abstracts tagged "cytokines"

Abstract Number: 1036 • 2014 ACR/ARHP Annual Meeting
Synergism Between GM-CSF and IL-17 Causes Enhanced Joint Pathology Via the Production of IL-6 and IL-23
Annemarie E.M. van Nieuwenhuijze¹, Debbie M. Roeleveld², Birgitte Walgreen², Miranda Bennink¹, Monique M. Helsen¹, Liduine van den Bersselaar¹, Ian P. Wicks³, Wim B. van den Berg¹, Fons A. van de Loo¹ and Marije I. Koenders¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Experimentel Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Inflammation, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia
Background/Purpose: T helper-17 (Th17) cells are important mediators of inflammatory diseases, and are the main pathogenic cell type in many animal models of autoimmunity. Recent…
Abstract Number: 1973 • 2014 ACR/ARHP Annual Meeting
Ectopic Lymphoid Neogenesis Is Strongly Associated with Activation of the IL-23/IL-17 Pathway in Rheumatoid Synovitis
Nataliya Yeremenko¹, Raquel Celis², Leonie M. van Duivenvoorde³, Julio Ramirez⁴, Iris C. Blijdorp⁵, Sara Marsal⁶, Jose L. Pablos⁷, Raimon Sanmarti⁴, Juan D. Cañete⁴ and Dominique L. Baeten¹, ¹Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ²Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ³Experimental Immunology, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁴Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ⁵Department of Clinical Immunology & Rheumatology, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology Research Group, Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ⁷Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain
Background/Purpose : The functional relevance of synovial ectopic lymphoid neogenesis (ELN) in rheumatoid arthritis (RA) remains unknown. As ELN correlates with the degree of tissue…
Abstract Number: 1001 • 2014 ACR/ARHP Annual Meeting
Fibroblast-like Synoviocytes Inhibit Wnt Signaling Pathway By Secreting Dockcop-1
Satoshi Yamasaki and Eiji Sugiyama, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: There is evidence of osteoclast activation in the inflamed joints of patients with rheumatoid arthritis (RA). Studies that focus on osteoblasts are not sufficient…
Abstract Number: 1965 • 2014 ACR/ARHP Annual Meeting
Characterization of the Thyroid Hormone System in Rheumatoid Arthritis
Anna-Sophia Pörings¹, Torsten Lowin², Luise Rauch¹, Tanja Späth¹, Angelika Graeber² and Rainer Straub³, ¹Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, Regensburg, Germany, ²Department of Internal Medicine I, Laboratory of Exp. Rheumatology and Neuroendocrino-Immunology, University Hospital of Regensburg, Regensburg, Germany, ³Internal Medicine, University Hospital Regensburg, Regensburg, Germany
Background/Purpose: Chronic inflammation is characterized by an energy appeal reaction supporting high energy demand of the activated immune system. Thyroid hormones are strongly associated with…
Abstract Number: 914 • 2014 ACR/ARHP Annual Meeting
A Predictive Model of Disease Outcome in Rituximab-Treated Myositis Patients Using Clinical Features, Autoantibodies, and Serum Biomarkers
Jeannette Olazagasti¹, Cynthia S. Crowson², Molly S. Hein¹, Consuelo Lopez de Padilla¹, Rohit Aggarwal³, Chester V. Oddis⁴ and Ann M. Reed¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic, Rochester, MN, ³Medicine, University of Pittsburgh, Pittsburgh, PA, ⁴Rheum/Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Develop predictive models of early (8 week) and late (24 week) disease outcomes using clinical features, autoantibodies, and serum biomarkers in patients with refractory…
Abstract Number: 1922 • 2014 ACR/ARHP Annual Meeting
Hydroxylchloroquine Use Is Associated with Decreased Soluble TNF Receptor Levels in SLE Patient Samples
Rufei Lu^1,2, Adam Przebinda³, Melissa E. Munroe⁴, Joel M. Guthridge¹, Joan T. Merrill⁵ and Judith A. James⁶, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disorder with a waxing and waning clinical course. Hydroxychloroquine (HCQ) is a well-tolerated and effective…
Abstract Number: 878 • 2014 ACR/ARHP Annual Meeting
Luminex and Autoantigen Microarray Analysis of Sera from Patients with Diffuse Cutaneous Systemic Sclerosis Reveals Changes Associated with Imatinib Mesylate Treatment
D. James Haddon¹, Hannah Wand², Paul J. Utz¹, Robert F. Spiera³, Jessica K. Gordon³ and Lorinda Chung⁴, ¹Medicine, Stanford University School of Medicine, Stanford, CA, ²Stanford University School of Medicine, Stanford, CA, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose Tyrosine kinase inhibitors (TKIs), including imatinib mesylate, have been studied for the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc). In a previously reported single…
Abstract Number: 2075 • 2013 ACR/ARHP Annual Meeting
Analysis Of The Associations Between Serum Ferritin and Cytokines In Pulmonary Disease Activity With Polymyositis/Dermatomyositis
Hidenaga Kawasumi, Takahisa Gono, Yasushi Kawaguchi, Yasuhiro Katsumata, Masanori Hanaoka, Sayuri Kataoka, Kae Takagi, Hisae Ichida, Sayumi Baba, Yuko Okamoto, Yuko Ota and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Polymyositis (PM) / dermatomyositis (DM) is occasionally complicated by interstitial lung disease (ILD), and ILD is a prognostic factor in PM/DM. We previously reported…
Abstract Number: 1150 • 2013 ACR/ARHP Annual Meeting
Differential Regulation Of IL-10 and Dusp1 Production By Kinases In The p38 MAPK Pathway
Deepa Hammaker¹, Katharyn Topolewski² and G. S. Firestein³, ¹MC 0656, UCSD School of Medicine, La Jolla, CA, ²UCSD School of Medicine, La Jolla, CA, ³Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: MAPK kinases MKK3 and MKK6 regulate p38 function in inflammatory diseases like rheumatoid arthritis (RA). Targeting MKK3 or MKK6 might be superior to traditional…
Abstract Number: 175 • 2013 ACR/ARHP Annual Meeting
Dynamics Of The Inflammatory Response In Rheumatoid Arthritis Patients Following Traumatic Injury: Insights From In Vivo,In Silico, and Single Nucleotide Polymorphism Studies
Rajaie Namas¹, Rami Namas², Harpreet Sagar³, Felix Fernandez-Madrid³, Timothy Billiar² and Yoram Vodovotz⁴, ¹Rheumatology, Wayne State University/ Henry Ford Health System, Detroit, MI, ²Surgery, University of Pittsburgh, Pittsburgh, PA, ³Internal Medicine/Rheumatology, Wayne State University, Detroit, MI, ⁴Surgery, Immunology, Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Both traumatic injury/hemorrhagic shock (T/HS) and rheumatoid arthritis (RA) are inflammatory diseases that are major sources of morbidity worldwide. We hypothesize that RA modifies…
Abstract Number: 1869 • 2013 ACR/ARHP Annual Meeting
Serum Cytokine/Chemokine Profiles Are Useful For Evaluating Pathological Conditions Of Rheumatoid Arthritis and Diagnosing Anti-CCP Antibody-Negative Patients
Hitoshi Uga¹, Takahiro Okazawa¹, Yoshiaki Miyamoto¹, Takehiro Hasegawa¹, Jun Saegusa², Goh Tsuji³, Sho Sendo⁴, Akio Morinobu⁵, Shunichi Kumagai^6,7 and Hirokazu Kurata¹, ¹Sysmex Corporation, Kobe, Japan, ²Department of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan, ³Center for Rheumatic Diseases, Shinko Hospital, Kobe, Japan, ⁴Center of rheumatic diseases, Shinko Hospital, Kobe, Japan, ⁵Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ⁶Center of rheumatic diseases, Shinko hospital, Kobe, Japan, ⁷Department of Evidence-Based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose: The diagnosis of anti-CCP antibody (ACPA) negative rheumatoid arthritis (RA) are known to be difficult and delayed as compared with ACPA-positive RA. This study…
Abstract Number: 953 • 2013 ACR/ARHP Annual Meeting
Baseline Serum Interleukin-34 Levels Predict Radiographic Progression In Rheumatoid Arthritis Patients
Sung Hae Chang^1,2, Byoung Youg Choi³, Hyon Joung Cho⁴, Hye Jin Oh⁵, Eun Ha Kang³, Yeong Wook Song^2,6 and Yun Jong Lee^2,7, ¹Internal Medicine Rheumatology, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ²Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ³Internal Medicine, Rheumatology, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ⁴Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ⁵Internal Medicine, Rheumatology, Seoul National University Hospital, Seoul, South Korea, ⁶Internal Medicine,Rheumatology, Seoul National University Hospital, Seoul, South Korea, ⁷Division of Rheumatology, Department of Internal Medicine,Seoul National University Bundang Hospital, Seongnam, South Korea
Background/Purpose: Interleukin-34 (IL-34), a novel cytokine playing a critical role in osteoclastogenesis, recently was reported that its expression increases in the synovial tissue and sera…
Abstract Number: 146 • 2013 ACR/ARHP Annual Meeting
The Arthritis Severity Locus Cia4 Is An Early Regulator of IL-6, IL-1β, and NFκB activators’ Expression in Pristane-Induced Arthritis
Max Brenner^1,2, Teresina Laragione^1,2 and Percio Gulko^1,2, ¹Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY, ²Molecular Medicine, Hosftra North Shore-LIJ School of Medicine, Manhasset, NY
Background/Purpose: Cia4 is a quantitative trait locus on rat chromosome 7 that regulates disease severity and joint damage in three models of rheumatoid arthritis including…
Abstract Number: 1859 • 2013 ACR/ARHP Annual Meeting
OX40⁺ T Cells and OX40L⁺ B Cells Accumulate In The Inflamed Joints and OX40 Signalling Is Skewed Towards Autoreactivity
Julie Kristine Laustsen¹, Tue Rasmussen², Malene Hvid³ and Bent Deleuran⁴, ¹Department of Medical Biomedicine, Aarhus University, Aarhus N, Denmark, ²Dept of Biomedicine, Aarhus University, Aarhus, Denmark, ³Dept. of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by the presence of autoantibodies and autoreactive T cells, leading to synovitis and joint destruction. The…
Abstract Number: 958 • 2013 ACR/ARHP Annual Meeting
Serum Cytokine Changes In Rituximab-Treated Rheumatoid Arthritis Patients
Tamarah D. de Jong¹, Saskia Vosslamber¹, Wilco de Jager², Hennie G. Raterman³, Alexandre E. Voskuyl⁴, Kyra A. Gelderman¹ and Cornelis L. Verweij⁵, ¹Pathology, VU University Medical Center, Amsterdam, Netherlands, ²Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁴Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁵Pathology and Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Although rituximab therapy is successful in the majority of rheumatoid arthritis (RA) patients, 30-40% of patients do not respond. The mechanism behind this is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].